Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Abrocitinib (Primary) ; Moxifloxacin
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Oct 2018 Status changed from recruiting to completed.
    • 04 Oct 2018 Planned End Date changed from 21 Sep 2018 to 1 Oct 2018.
    • 04 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top